Testing effectiveness (Phase 2)Study completedNCT00560794
What this trial is testing
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
Who this might be right for
Acute Lymphoblastic Leukemia
Amgen Research (Munich) GmbH 21